7MW 3711
Alternative Names: 7MW-3711Latest Information Update: 04 Jun 2025
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Small cell lung cancer; Solid tumours
Most Recent Events
- 23 May 2025 Efficacy and adverse events data from a phase-I/II clinical trials in small cell lung cancer released by Mabwell
- 23 May 2025 Efficacy and adverse events data from a phase-I/II clinical trials in Solid tumours released by Mabwell
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumor presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)